Quotient Sciences is to invest £6.3 million to expand drug substance manufacturing at the site in Alnwick, UK, which it acquired along with Arcinova in February. This will also create 80 new jobs over the next three years and boost its capacity to develop complex medicines tenfold.

Two pharmaceutical CDMOs, AMRI in the US and UK-based Arcinova, have almost simultaneously announced full corporate rebranding exercises. The former has become Curia, which is derived from a Latin word for ‘purposeful assembly’, as of 12 July, while the latter is taking the name Quotient Sciences – Alnwick.

UK-based CDMO Arcinova has been acquired by Quotient Sciences, a ‘drug development and manufacturing accelerator’ that is itself owned by private equity firm Permira. BGF, which had part-owned Arcinova since 2018, will withdraw from its minority stake. Terms were not disclosed.